Stockscreener 앱 받기
0.32
0.56%
-0.0015
시간 외 거래:
.33
0.01
+3.13%
전일 마감가:
$0.3215
열려 있는:
$0.3226
하루 거래량:
545.51K
Relative Volume:
0.52
시가총액:
$22.84M
수익:
-
순이익/손실:
$-30.01M
주가수익비율:
-0.2623
EPS:
-1.22
순현금흐름:
$-23.94M
1주 성능:
-4.85%
1개월 성능:
-32.69%
6개월 성능:
-68.35%
1년 성능:
-56.50%
1일 변동 폭
$0.3036
$0.35
1주일 범위
$0.3036
$0.3618
52주 변동 폭
$0.217
$2.48
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| INAB | 0.32 | 22.84M | 0 | -30.01M | -23.94M | -1.22 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - The Manila Times
Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire
10 Biggest Biotechnology Companies - Investopedia
TāStation®'s analytical power used to resolve a central question about sweet taste perception - EurekAlert
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World
Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World
Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World
Gritstone bio : Bankruptcy Form 8 K - Marketscreener.com
US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results - Yahoo Finance
bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call Transcript - Insider Monkey
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... - Yahoo Finance
SEC Form SC 13G filed by Bio-Rad Laboratories Inc. - Quantisnow
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance - BioSpace
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit - GlobeNewswire
NJ Bio, Inc. Wins Best CRO Award at 15th Annual World ADC Conference - Joplin Globe
Kronos Bio : Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives Form 8 K - Marketscreener.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - Quantisnow
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress - Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - GlobeNewswire
Gossamer Bio Grants 183K Stock Options to New Hires at $0.88 Per Share | GOSS Stock News - StockTitan
BioRestorative Therapies Enters at-the-Market Offering Agreement with Rodman & Renshaw LLC - Defense World
National Fuel Gas Updates Investor Presentation in Current ReportNational Fuel Gas Company (NYSE: NFG) has made notable updates to its Investor Presentation as detailed in a recent 8-K filing with the Securities and Exchange Commission on November - Defense World
BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES - The Malaysian Reserve
Annovis Bio Inc (ANVS) Quarterly 10-Q Report - Quartzy
Telesis Bio: Q3 Earnings Snapshot - New Haven Register
TELA Bio Inc (TELA) Quarterly 10-Q Report - Quartzy
Mustang Bio Inc (MBIO) Quarterly 10-Q Report - Quartzy
Pharma Pulse 11/8/24: Dusting Off One’s Cost Center Hat, Iron Supplements Benefit Children with HIV & more - Pharmaceutical Executive
TELA Bio Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter 2024 Results Call - BioSpace
Secura Bio Announces Poster Presentation Highlighting New - GlobeNewswire
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call - Business Wire
[Latest] Global Cancer Cell Analysis Market Size/Share - GlobeNewswire
Secura Bio Announces Poster Presentation Highlighting New COPIKTRA® (duvelisib) Data for the Treatment of Patients With Peripheral T-Cell Lymphoma and Other Advanced Hematologic Malignancies at the 2024 American Society of Hematology Meeting - The Manila Times
Nuvation Bio Inc. (NUVB): Promising Penny Stock with Strong Oncology Pipeline - Yahoo Finance
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability - Quantisnow
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference - StockTitan
bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies - Yahoo Finance
OrbiMed Advisors LLC Reduces Stake in TELA Bio Inc - Yahoo Finance
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares - Yahoo Finance UK
Upstream Bio Rings the Opening Bell - Nasdaq
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development - Yahoo Finance UK
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum - Lelezard
Average rate on a 30-year mortgage in the US rises to the highest level in 8 weeks - Yahoo Finance
Cresco Labs to Report Third Quarter 2024 Financial Results on November 8, 2024 - Yahoo Finance
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.56%
자본화:
|
볼륨(24시간):